IP Library Granted Patent US 10,100,288
Granted Patent B2
US 10,100,288 · App. 15/915,927 · Granted Oct 16, 2018

Ketoreductase polypeptides for the reduction of acetophenones

Inventors: Jack Liang (San Mateo, CA); Stephane J. Jenne (Foster City, CA); Emily Mundorff (Garden City, NY); Charlene Ching (San Jose, CA); John M. Gruber (Mountain View, CA); Anke Krebber (Palo Alto, CA); Gjalt W. Hiusman (Redwood City, CA)
Assignee: Codexis, Inc.
C12N9/0006C12P7/22C12Y101/01184C12Y101/01Y02E50/17Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,100,288
App. No.
15/915,927
Granted
Oct 16, 2018
Kind
B2
Abstract

The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.

Claims (23)

1. An engineered polynucleotide encoding an engineered ketoreductase polypeptide derived from a wild-type Lactobacillus ketoreductase having ketoreductase activity, wherein said engineered ketoreductase polypeptide is capable of converting in less than 24 hours, at least 95% of the 2′,6′-dichloro-3′-fluoroacetophenone substrate to (S)-1-(2,6-dichloro-3-fluorophenyl) ethanol product when carried out at an amount of less than 1% by weight with respect to the amount of the 2′,6′-dichloro-3′-fluoroacetophenone substrate, wherein said engineered ketoreductase polypeptide comprises an amino acid sequence at least 90% identical to SEQ ID NO: 2, 4, or 98, wherein the amino acid sequence of said engineered ketoreductase polypeptide comprises a proline at a position corresponding to position 190 of SEQ ID NO: 2, 4, or 98, and further wherein said amino acid sequence of said engineered ketoreductase polypeptide has at least one substitution at a position corresponding to a position in SEQ ID NO: 2, 4, or 98, selected from:

the residue at the position corresponding to position 7 is threonine, proline, tryptophan, arginine, histidine, or asparagine;

the residue at the position corresponding to position 16 is serine;

the residue at the position corresponding to position 43 is isoleucine;

the residue at the position corresponding to position 60 is alanine;

the residue at the position corresponding to position 94 is alanine, valine or cysteine;

the residue at the position corresponding to position 95 is isoleucine or leucine;

the residue at the position corresponding to position 96 is serine, asparagine, threonine or glutamic acid;

the residue at the position corresponding to position 97 is lysine, threonine, valine, arginine, methionine, or isoleucine;

the residue at the position corresponding to position 120 is phenylalanine or valine;

the residue at the position corresponding to position 125 is glycine or serine;

the residue at the position corresponding to position 142 is asparagine;

the residue at the position corresponding to position 147 is phenylalanine, leucine, isoleucine, valine, or glutamine;

the residue at the position corresponding to position 149 is glycine or phenylalanine;

the residue at the position corresponding to position 150 is aspartic acid or histidine;

the residue at the position corresponding to position 152 is serine, threonine, or methionine;

the residue at the position corresponding to position 196 is valine, methionine, phenylalanine, or isoleucine;

the residue at the position corresponding to position 202 is alanine, tryptophan, tyrosine, or methionine;

the residue at the position corresponding to position 205 is arginine;

the residue at the position corresponding to position 206 is methionine or tyrosine: and

wherein optionally the amino acid sequence has one or more residue differences at other amino acid residues as compared to SEQ ID NO: 2, 4, or 98.

2. The engineered polynucleotide encoding the engineered ketoreductase polypeptide of claim 1 , wherein said engineered ketoreductase polypeptide is further capable of reducing the substrate to the product at a rate greater than the rate capable by the ketoreductase polypeptide having the sequence of SEQ ID NO:6.

3. The engineered polynucleotide encoding the engineered ketoreductase polypeptide of claim 1 , wherein said engineered ketoreductase polypeptide is further capable of reducing the substrate to the product at a rate that is at least 1500% greater than the rate capable by the ketoreductase polypeptide having the sequence of SEQ ID NO:6.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (8)
Continuation 15840381 · Dec 13, 2017
Continuation 15353165 · Nov 16, 2016
Division 14501416 · Sep 30, 2014
Continuation 13970284 · Aug 19, 2013
Continuation 13682600 · Nov 20, 2012
Division 12210195 · Sep 13, 2008
Provisional Application 60972058 · Sep 13, 2007
Related Publication 20180201909A1 · Jul 19, 2018
Cited By (1)
US 12,415,990